Please login to the form below

Not currently logged in

type 2 diabetes

This page shows the latest type 2 diabetes news and features for those working in and with pharma, biotech and healthcare.

Google boosts healthcare business with new hire

Google boosts healthcare business with new hire

This allows identification and characterisation of inflammatory disease mechanisms. Verily has also entered the diabetes space, teaming up Sanofi to create Onduo, a platform that combines devices, software, medicine and professional ... with type 2

Latest news

More from news
Approximately 29 fully matching, plus 472 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 5 fully matching, plus 35 partially matching documents found.

Latest appointments

  • Roche’s Torsten Hoffmann to join Zealand Pharma Roche’s Torsten Hoffmann to join Zealand Pharma

    In his new role at Zealand, Dr Hoffmann joins a more compact company focused on the discovery of drugs in cardio-metabolic diseases, diabetes and obesity. ... Its lead product is the GLP-1 agonist lixisenatide, which is licensed to Sanofi who markets it

  • bmore creative hires Kush Rach as new business director bmore creative hires Kush Rach as new business director

    He was a key account manager at the pharma company, where he worked in the diabetes therapeutic area, and was involved in the UK launch of Galvus (vildagliptin) for type 2 ... diabetes. Ben Blackmore, bmore creative's MD, told The Directory: "We are

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • World Diabetes Day: Interaction and impact of diabetes on mental health

    and Smith, B.D., 2018. The Importance of Addressing Depression and Diabetes Distress in Adults with Type 2 Diabetes. ... and Goswami, S., 2018. Type 2 diabetes and influence of diabetes-specific distress on depression.

  • Evaluating the potential of a pre-launch prodct in a real-life setting

    Our client was developing a new product for treating Type 2 diabetes, which they were preparing for launch. ... In an increasingly competitive diabetes market, with new brands and formulations frequently becoming available, our client needed to determine

  • New insights into making behavioural change work

    Lifestyle conditions, or noncommunicable diseases (NCDs), include obesity, type 2 diabetes mellitus, cardiovascular disease and atherosclerosis [1]. ... References. 1. World Health Organization. Noncommunicable diseases (fact sheet 355). Available at: .

  • Getting personal with wearable tech

    In partnership with Diabetes UK and Hewlett Packard it is deploying mobile health self-management tools (wearable sensors and software) for people with Type 1 and Type 2 diabetes to

  • Dissecting adherence to personalise patient support

    Tailoring the approach to each distinct type. Distinguishing between the two types of non-adherence can better inform patient compliance efforts and clinical practice. ... IMS Institute for Healthcare Informatics (2016). Improving Type 2 Diabetes Therapy

More from PMHub
Approximately 1 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Six Degrees Medical Consulting

Partnering with top global pharmaceutical companies, we push the boundaries to create meaningful, impactful and lasting learning opportunities. We leverage...

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...